Randall B. Brenner - Oct 28, 2022 Form 4 Insider Report for Paratek Pharmaceuticals, Inc. (PRTK)

Role: Chief Development & Regulatory
Signature: /s/ William M. Haskel, Attorney-in-Fact for Randall B. Brenner
Stock symbol: PRTK
Transactions as of: Oct 28, 2022
Transactions value $: -$12,201
Form type: 4
Date filed: 11/1/2022, 07:53 PM
Previous filing: Oct 27, 2022
Next filing: Dec 14, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	PRTK	Common Stock	Sale	-$12.2K	-3.52K	-0.98%	$3.47	354K	Oct 28, 2022	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Sale of shares to cover personal income tax obligations upon vesting of performance-based restricted stock units, as previously reported in a Form 4 filed with the Securities and Exchange Commission (the "SEC") on October 27, 2022, pursuant to a Rule 10b5-1 trading plan.
F2	The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions ranging from $3.43 to $3.55. The Reporting Person undertakes to provide to Paratek Pharmaceuticals, Inc., any security holder of Paratek Pharmaceuticals, Inc., or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 3 to this Form 4.

Content

Sale of shares to cover personal income tax obligations upon vesting of performance-based restricted stock units, as previously reported in a Form 4 filed with the Securities and Exchange Commission (the "SEC") on October 27, 2022, pursuant to a Rule 10b5-1 trading plan.

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions ranging from $3.43 to $3.55. The Reporting Person undertakes to provide to Paratek Pharmaceuticals, Inc., any security holder of Paratek Pharmaceuticals, Inc., or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 3 to this Form 4.